To study the effects of two ayurvedic formulations, Amrita Gugglu and Sudarshan Churna Tablet in the treatment of joints pain after Chikungunya fever

Clinical study on Amrita Gugglu and Sudarshan Churna Tablet in the management of Post-Chikungunya Chronic Inflammatory Arthritis - An open randomized comparative trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/03/018013

Enrollment

Registered

2019-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M129- Arthropathy, unspecified Health Condition 2: A00-B99- Certain infectious and parasitic diseases Health Condition 3: M12- Other and unspecified arthropathy Health Condition 4: M028- Other reactive arthropathies

Interventions

Intervention1: Amrita Gugglu and Sudarshana Churna Tablet: Amrita Gugglu 2 vati (500 mg each) tds and Sudarshana Churna Tablet 4 Tablets (500 mg each) tds will be given with plain water after foo

Eligibility

Inclusion criteria

Inclusion criteria: Patients having symptoms of Post-Chikungunya chronic inflammatory arthritis with history of Chikungunya fever will be selected from OPD and IPD of IPGT and RA Hospital, Jamnagar.

Exclusion criteria

Exclusion criteria: Age less than 18 years more than 70 years. Patients having previous Rheumatological diseases, Gout, Psoriatic arthritis, fibromyalgia and SLE etc. Pregnant and lactating women. Other chronic debilitating disease like STD, tuberculosis, hypertension and carcinoma etc.

Design outcomes

Primary

Measure	Time frame
EfficacyTimepoint: Two Month	—

Secondary

Measure	Time frame
SafetyTimepoint: Two Month	—

Countries

India

Contacts

Public ContactSachin Kumar Sharma

IPGT and RA Gujarat ayurved university

alankruta@yahoo.com9824171817

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026